Background: Why revisit existing genomic data?

A tool called Talos has been developed to automatically reanalyze genomic data from people with rare diseases. A Nature Medicine Research Briefing reports that the tool could make frequent reanalysis available at large scale and low cost. The work focuses on repeatedly reviewing existing genomic data for diagnostic purposes.

One reason to revisit genomic data is that the knowledge used to interpret them changes. Prior studies cited in the briefing include a review of factors associated with additional diagnoses after reanalysis and research examining changes in the composition of rare disease gene panels. When and how often to revisit existing data is therefore a challenge for diagnostic practice.

The same briefing describes an overall diagnostic yield of 10% in a 2022 systematic review and meta-analysis of 29 reanalysis studies. This figure combines results from earlier studies; it is not Talos’s diagnostic yield and does not indicate an individual patient’s likelihood of receiving a diagnosis.

Key findings: The scale and cost of automated reanalysis

The researchers developed Talos and reported that frequent reanalysis of genomic data from people with rare diseases could be provided at large scale and low cost. Talos is open source. The briefing explains that this approach to sharing the tool enables broad adoption by the clinical and research communities.

However, the available public text does not specify the number of participants, the interval between reanalyses, the number of additional diagnoses, or the cost per patient. These materials alone do not make it possible to determine how much costs fell or whether diagnostic performance is better than manual reanalysis or other tools. The sequencing platforms and variant types supported, as well as the specific analytical algorithms, could not be confirmed either.

The nature of the source should also be distinguished. Published on June 29, 2026, the material is a Research Briefing summarizing the original study. The study it describes is Welland et al., “Automated reanalysis of genomic data for rare disease diagnostics at scale”; its DOI is 10.1038/s41591-026-04477-5. The materials available for this article do not include the main text, methods, or supplementary information of the original study.

Meaning and outlook: Connecting repeated analysis to diagnostic practice

Talos points toward making the review of existing genomic data a repeatable diagnostic workflow. The reported potential for large-scale, low-cost provision and the open-source release give institutions a starting point for considering whether to adopt automated reanalysis.

To assess implementation, institutions need to establish which patients and data yielded additional diagnoses, and what staff and procedures are needed to review the results. Running automated reanalysis alone should not be taken to mean that a patient’s diagnosis has been confirmed. Whether it shortens time to diagnosis or improves treatment decisions or patient outcomes also requires separate evidence.

The available materials support three central points: an automated reanalysis tool was developed; frequent reanalysis may be provided at large scale and low cost; and the tool was released as open source. Its specific performance and conditions for use remain to be assessed after examining the original study’s detailed results. Source: Nature Medicine Research Briefing: https://www.nature.com/articles/s41591-026-04516-1